


PHARMACEUTICAL 2017



Eterna Therapeutics Inc. Rank 188 of 292





PHARMACEUTICAL 2017



Eterna Therapeutics Inc. Rank 188 of 292

The relative strengths and weaknesses of Eterna Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eterna Therapeutics Inc. compared to the market average is the variable Other Revenues, increasing the Economic Capital Ratio by 114% points. The greatest weakness of Eterna Therapeutics Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 97% points.

The company's Economic Capital Ratio, given in the ranking table, is 28%, being 25% points above the market average of 2.9%.

Input Variable	Value in 1000 USD
Assets, Current	10,662
Cost of Goods Sold	0
Intangible Assets	966
Liabilities, Current	6,643
Liabilities, Non-Current	12
Other Assets	1,966
Other Compr. Net Income	51
Other Expenses	8,170
Other Liabilities	5,972
Other Net Income	-607
Other Revenues	22,312
Property and Equipment	3,101
Research and Development	0
Selling, General and Administrative Expense	16,458

Output Variable	Value in 1000 USD
Assets	16,695
Liabilities	12,627
Expenses	24,628
Revenues	22,312
Stockholders Equity	4,068
Net Income	-2,923
Comprehensive Net Income	-2,898
Economic Capital Ratio	28%

